Sesquiterpenic acid

Sesquiterpenic Acid

1. Identity and Chemical Classification

"Sesquiterpenic acid" is not a single discrete compound but rather a chemical class designation encompassing all sesquiterpenoids that carry a carboxylic acid functional group. The broader parent class — the sesquiterpenes — are defined by their 15-carbon (C₁₅) skeleton constructed from three isoprene units. Sesquiterpenes are C₁₅-terpenoids built from three isoprene units, found particularly in higher plants and in many other living systems such as marine organisms and fungi, and they occur naturally as hydrocarbons or in oxygenated forms including lactones, alcohols, acids, aldehydes, and ketones. When the oxygenated form is specifically a carboxylic acid (–COOH) moiety attached to the sesquiterpene core skeleton, the compound belongs to the sesquiterpenic acid sub-class.

Sesquiterpenes as a whole are widely distributed across higher plants, marine organisms, fungi, and some invertebrates, exhibiting remarkable structural diversity that encompasses over 10,000 identified variants with more than 300 distinct carbon skeletons, ranging from acyclic chains to mono-, bi-, tri-, and even tetracyclic forms, often featuring functional groups such as alcohols, aldehydes, ketones, lactones, or oxides.

The most pharmacologically studied sesquiterpenic acids include:

• Valerenic acid (Valeriana officinalis) — a bicyclic sesquiterpene carboxylic acid; the principal acid-form constituent of valerian root.
• Boswellic acids (multiple compounds, primarily from Boswellia serrata) — pentacyclic triterpenic acids structurally described alongside sesquiterpenic frameworks in the resin literature, and the most clinically investigated acid-type terpenoids from resinous plants.
• Cadinane-type sesquiterpenic acids — isolated from Leucanthemopsis pulverulenta (Compositae) and related Asteraceae species.

From Leucanthemopsis pulverulenta (Compositae), ten new sesquiterpenic acids have been isolated, with structures and absolute stereochemistry assigned by spectral and chemical evidence; they are the first carboxylic acid members of the cadinane and munrolane series to be found in a natural source.

Valerenic acid (VA) is isolated from V. officinalis and has a sesquiterpene carboxylic acid skeletal structure, which is considered one of the major active compounds of the plant. Valerenic acid is a sesquiterpene that can be effectively used against inflammation and cancer, and it is a component of Valeriana officinalis.

2. Biosynthesis and Natural Sources

The biosynthesis of sesquiterpenic acids proceeds through the universal terpenoid pathway. The biosynthesis of terpenes results from the condensation of five-carbon isoprene building blocks of dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP); prenyltransferases catalyze chain elongation from these building blocks to yield polyisoprenoid diphosphates such as geranyl diphosphate (GPP, C10) and farnesyl diphosphate (FPP, C15); terpene synthases then catalyze cyclization or rearrangement of these polyisoprenoid diphosphates to yield sesquiterpenes among other terpenoid classes.

Sesquiterpenoids are a class of enormously diverse natural products derived from the 15-carbon precursor, farnesyl pyrophosphate (FPP); the chemical diversity of sesquiterpenoids starts from diverse sesquiterpene hydrocarbon backbones created by carbocation cascade reactions in sesquiterpene synthases, and the C₁₅ sesquiterpene skeletons are then often oxygenated by regio- and stereo-selective cytochrome P450 monooxygenases.

Key botanical sources of sesquiterpenic acids include:

• Valeriana officinalis L. (Caprifoliaceae) — valerian root and rhizome, the primary source of valerenic acid and its derivatives (acetoxy-valerenic acid, hydroxy-valerenic acid).
• Leucanthemopsis pulverulenta and related Compositae/Asteraceae — sources of cadinane- and munrolane-type sesquiterpenic acids.
• Inula wissmanniana and related Inula species — sources of novel sesquiterpenic acid structures.
• Asteraceae family broadly — sesquiterpene lactones (the lactone sub-class closely related to sesquiterpenic acids) are characterized by their high prevalence in the Asteraceae family and are one of the major groups of secondary metabolites found in plants.
• Marine organisms and fungi — sesquiterpene lactones with unusual structure have been isolated from various natural sources including fungi, plants, and marine growth.

Sesquiterpenoids are the largest class of natural terpenoids, with a structural diversity that includes thousands of compounds and more than 100 skeletal types; many of them show "drug-like" chemical properties, including alkylating center reactivity, lipophilicity, and favorable molecular geometry and electronic features.

3. Common Forms and Preparations

Sesquiterpenic acids as a class are encountered in commerce and research in several forms:

• Standardized dried root or rhizome extracts — for valerenic acid, the most widely used preparation is a hydroethanolic extract of Valeriana officinalis root, often standardized to 0.8% or higher valerenic acids by HPLC. Valerian roots improve the subjective experience of sleep when taken in the evening; the constituents include valepotriates (iridoids) and volatile oil, including monoterpenes and sesquiterpenes (valerenic acids).
• Oleo-gum-resin preparations — boswellic acids are delivered as standardized extracts of Boswellia gum resin (e.g., Aflapin®, 5-Loxin®), enriched to specified percentages of AKBA (acetyl-keto-boswellic acid). Boswellia has been most often studied at dosages of 100–250 mg/day of the Aflapin and 5-Loxin formulations.
• Essential oils — sesquiterpenic acids are components of essential oils from numerous aromatic plants, alongside hydrocarbon sesquiterpenes. Sesquiterpenoids are mainly found in essential oils, detected by GC-MS analysis.
• Isolated pure compounds — used principally in pharmacological and mechanistic research.
• Capsules, tablets, and tinctures — commercial dosage forms for valerian and Boswellia extracts, as used in clinical trials.

4. Traditional and Historical Use

4.1 Valerian Root (Valeriana officinalis)

Valerian (Valeriana officinalis L.; Caprifoliaceae) has long been used as a natural remedy for promoting sleep and relaxation, with its medicinal application dating back to ancient Greece and Rome; over centuries, valerian root has been utilized to alleviate insomnia, nervousness, and restlessness, and it remains one of the most widely used herbal sleep aids in modern phytotherapy.

The extracts derived from the roots of the plant are commonly used for the treatment of sleeping disorders and anxiety since it has been shown that V. officinalis products have sedative and anxiolytic properties; the German scientific advisory board of the Federal Institute for Drugs and Medical Devices (Commission E) has approved V. officinalis for the cure of sleeping disorders.

4.2 Boswellia / Frankincense (Boswellia serrata and related species)

In Ayurveda, frankincense, known as "Shallaki" (Boswellia serrata Roxb. ex Colebr., Burseraceae), has been used for centuries to treat inflammatory conditions, joint disorders, and respiratory ailments; Ayurvedic formulations often combine frankincense with other botanicals to enhance its therapeutic efficacy, particularly in managing rheumatoid arthritis (Amavata) and osteoarthritis.

In Traditional Chinese Medicine (TCM), frankincense ("Ru Xiang") is highly valued for its ability to promote blood circulation, reduce swelling, and alleviate pain; it is frequently used in combination with myrrh ("Mo Yao"), obtained from trees of Commiphora myrrha, to treat traumatic injuries, inflammation, and chronic pain conditions.

4.3 Broader Asteraceae and Compositae Traditions

Studies of folk medicines implicate sesquiterpene lactones — structurally related to sesquiterpenic acids — as the active ingredient in many treatments for ailments such as diarrhea, burns, influenza, and neurodegeneration. Within the Asteraceae, sesquiterpenic acids and lactones have served as the chemical basis for traditional anti-inflammatory, antiparasitic, and digestive preparations across numerous cultures worldwide for centuries.

5. Key Constituents and Active Compounds

Valerian contains more than 150 chemical compounds with diverse physiological activities. Within this complex, the sesquiterpenic acids represent a defined and pharmacologically significant fraction. The principal individually characterized sesquiterpenic acids of current research interest are:

5.1 Valerenic Acid and Derivatives

In analyzed modulation of GABA_A receptors by VA, acetoxy-VA, and hydroxy-VA (all constituents of valerian root), a principal finding is that only VA (but neither acetoxy-VA nor hydroxy-VA) acts as a positive allosteric modulator of GABA_A receptors.

Valerenic acid stimulates chloride currents through GABA_A receptors; to analyze the molecular basis of VA action, GABA_A receptors with 13 different subunit compositions were expressed in Xenopus oocytes, revealing a subtype-dependent stimulation — only channels incorporating β2 or β3 subunits were stimulated by VA, while replacing β2/3 by β1 drastically reduced sensitivity.

5.2 Boswellic Acids

The β-pentacyclic triterpene acids in Boswellia serrata — including 3-acetyl-11-keto-β-boswellic acid (AKBBA), 11-keto-β-boswellic acid (KBBA), β-boswellic acid (BBA), and 3-acetyl-β-boswellic acid (ABBA) — represent the major bioactive boswellic acids in the gum resin.

This dual inhibitory action on the inflammatory process is unique to boswellic acids; of these, 3-acetyl-11-keto-β-boswellic acid (AKBA) is the most potent inhibitor of 5-lipoxygenase (5-LO), an enzyme responsible for inflammation.

5.3 Other Notable Sesquiterpenic Acids

The cadinane-series carboxylic acids from Leucanthemopsis pulverulenta and munrolane-series acids from the same plant represent structurally novel sesquiterpenic acids. Zerumbone — found in Zingiber zerumbet and related to sesquiterpene oxygenated forms — causes phosphorylation and degradation of IκB proteins, which blocks the functioning of the IKK complex, leading to decreased translocation of NF-κB into the nucleus.

6. Established Mechanisms of Action

6.1 GABAergic Modulation (Valerenic Acid)

The mechanism of action of valerenic acid involves allosteric modulation of GABA_A receptors, and valerian extracts may inhibit brain GABA metabolism, contributing to their sedative and anxiolytic properties.

Valerian extract and valerenic acid have been shown to inhibit the firing rate of rat brainstem neurons, with this effect being antagonized by bicuculline (a GABA_A antagonist), suggesting that valerenic acid may be a crucial component in the modulation of GABAergic function observed with valerian extracts.

Valerenic acid has been reported to enhance GABA-evoked currents in cultured hippocampal neurons at 10 μM and recombinant GABA_A receptors at 1–30 μM, indicating a positive modulatory action; reported plasma levels of valerenic acid in humans were in a range that corresponds to its minimum effective concentration (1 µM).

6.2 Adenosine Receptor Modulation (Valerenic Acid)

Beyond direct adenosine-mediated effects, valerenic acid has been identified as a potent positive allosteric modulator (PAM) of the A1 adenosine receptor (A1AR), with valerian extract Ze 911 identified as a distinctive pharmacological tool for modulating A1AR activity; valerian has long been used as a natural remedy for promoting sleep and relaxation, with its medicinal application dating back to ancient Greece and Rome.

Pharmacological studies suggest that valerian may exert its effects through multiple neuromodulatory pathways, including interactions with the adenosine, serotonin, and GABAergic systems.

6.3 5-Lipoxygenase Inhibition (Boswellic Acids)

Acetyl-boswellic acids exhibit anti-inflammatory behaviour by inhibiting leukotriene synthesis; the enzyme 5-lipoxygenase is inhibited through a non-redox reaction; specifically, 3-acetyl-11-keto-beta-boswellic acid binds as an allosteric partial inhibitor, initiating a shift in regioselectivity of the catalyzed reaction.

6.4 NF-κB Pathway Inhibition

Valerenic acid is a strong inhibitor of cytokine and NF-κB activation. This mechanism is shared with other sesquiterpenic acid-containing fractions. In RAW264.7 cells, certain sesquiterpene mechanisms of action involve the degradation of IκB proteins and inhibition of translocation of the NF-κB complex into the nucleus.

6.5 Antiproliferative and Proapoptotic Mechanisms

Sesquiterpenes and their derivatives are characteristically associated with plant defence mechanisms owing to their antifungal, antibacterial, and antiviral activities; over the last two decades, these compounds have been reportedly demonstrated to have health-promoting perspectives against a wide range of metabolic syndromes including hyperglycemia, hyperlipidemia, cardiovascular complications, neural disorders, diabetes, and cancer.

Sesquiterpene lactones and related acid-type compounds have been shown to disrupt cellular redox balance and induce oxidative stress in cancer cells; oxidative stress is associated with increased production of reactive oxygen species (ROS) which can promote many aspects of cancer development and progression; on the other hand, ROS which initiate apoptosis via the mitochondrial-dependent pathway can also be used to kill cancer cells.

7. Scientific Evidence by Area of Use

7.1 Sleep Disorders and Insomnia

The most extensively studied sesquiterpenic acid in this area is valerenic acid from Valeriana officinalis. Clinical evidence is mixed but has produced positive findings in several trials.

A randomized, double-blind, placebo-controlled clinical study evaluated standardized extract of Valeriana officinalis for overall sleep quality in human subjects with sleep complaints (Advances in Therapy, January 2024;41(1):246–261).

A systematic review of clinical trials cast doubt on the efficacy of valerian or valerian combinations to improve subjective or objective sleep parameters, and notably, the highest quality studies were even less likely to find a statistical benefit for valerian over placebo.

Valerenic acid selectively modulates GABA_A receptors containing β2- or β3-subunits while displaying only negligible effects on GABA_A receptors incorporating β1-subunits; in vivo, VA induces anxiolytic and anticonvulsive effects; most notably, VA does not significantly reduce locomotor activity even at high doses.

Evidence strength: The in vitro and animal mechanistic data for valerenic acid as a GABA_A positive allosteric modulator are well-replicated. Clinical evidence from human trials remains inconsistent: some randomized controlled trials report modest improvements in sleep latency and quality, but high-quality systematic reviews have not confirmed consistent superiority over placebo. Methodological heterogeneity between trials (in extract standardization, dosage, and outcome measures) is a primary limitation.

7.2 Anxiety

Valerenic acid, the main component of valerian extract (VE), allosterically modulates GABA_A receptors and, in this way, is thought to induce anxiolytic activity.

Ten phytomedicines have been identified as having preclinical investigations showing interaction with the GABA system in addition to human clinical trials — including valerian; collectively, the literature reveals preclinical and clinical evidence for various phytomedicines modulating GABA pathways, with comparative anxiolytic effect to the current array of pharmaceuticals, along with good safety and tolerability profiles.

Valerian is also considered useful as an anxiolytic when administered during the daytime at doses up to 250 mg three times per day.

Evidence strength: Preclinical evidence is robust; human clinical data are preliminary and limited in scale, with current evidence classified as insufficient to draw firm conclusions about standalone anxiolytic efficacy at standard doses.

7.3 Joint Inflammation and Osteoarthritis (Boswellic Acids)

This area carries the strongest clinical evidence for any acid-type terpenoid natural product.

Boswellia serrata was considered a potent anti-inflammatory, anti-arthritic, and analgesic agent; in a meta-analysis, data from randomized controlled trials were obtained to assess the effects of Boswellia or its extract versus placebo in patients with osteoarthritis; seven trials involving 545 patients were included; compared with the control group, Boswellia and its extract may relieve the pain (VAS: WMD −8.33; 95% CI −11.19, −5.46; P < 0.00001; WOMAC pain: WMD −14.22; 95% CI −22.34, −6.09; P = 0.0006).

In multiple randomized, double-blind, placebo-controlled trials involving osteoarthritis patients, Boswellia serrata-derived formulations enriched in boswellic acids — such as Boswel®, Aflapin®, and 5-Loxin® — were found to significantly improve pain scores, joint stiffness, and functional impairment; some formulations also demonstrated the ability to reduce inflammatory markers (e.g., TNF-α, IL-6, CRP) and matrix metalloproteinases (MMPs).

A Cochrane review of randomized controlled studies of herbal remedies, including B. serrata, for treatment of osteoarthritis reported high-quality evidence from 2 studies indicating that enriched B. serrata extract improved symptoms compared to placebo.

Evidence strength: Moderate to good for symptomatic relief in knee osteoarthritis, supported by multiple RCTs and a Cochrane-level systematic review. Long-term disease-modifying effects have not been established.

7.4 Inflammatory Bowel Disease

In patients with inflammatory bowel diseases (IBD), including Crohn's disease and chronic colitis, Boswellia extracts significantly improved clinical scores and remission rates, suggesting modulatory effects on intestinal mucosal inflammation.

Clinical trials have investigated the effectiveness of boswellic acids in treating ulcerative colitis, but a study on chemically induced colitis in mouse models showed little effectiveness.

Evidence strength: Preliminary. Small clinical trials in Crohn's disease and colitis show favorable trends, but sample sizes are limited and evidence is insufficient for definitive therapeutic conclusions.

7.5 Asthma and Respiratory Inflammation

Boswellic acids are thought to decrease the symptoms of asthma; a small 1998 placebo-controlled trial of Boswellia extract for the treatment of asthma showed good results.

Boswellic acids, the triterpenes present in the gum resins of B. serrata (Burseraceae), have been traditionally used in the Ayurvedic system of medicine as antioxidant and anti-inflammatory agents to manage diseases such as rheumatoid arthritis, chronic bronchitis, asthma, and chronic inflammatory bowel diseases.

Evidence strength: Very preliminary. Only small pilot studies exist, and larger replications are lacking.

7.6 Antimicrobial and Antifungal Activity

Sesquiterpenoids, with abundant structural skeleton types and a wide range of bioactivities, are considered good candidates to be antibacterial and antifungal agents; in the past decades, many sesquiterpenoids were isolated from plants and fungi exhibiting good antibacterial and antifungal activities.

Drimane-type sesquiterpenic acids and their derivatives from Drimys winteri (Winteraceae) have been specifically evaluated for antimicrobial properties. Sesquiterpene drimanes isolated from Drimys winteri have shown interesting antimicrobial properties.

Evidence strength: Preclinical only (in vitro). Antimicrobial and antifungal data for sesquiterpenic acids are almost entirely from cell culture and minimal-inhibitory-concentration assays, with no human clinical evidence available.

7.7 Anticancer Activity

The high potential of sesquiterpenes and their derivatives against various cancers including breast, colon, bladder, pancreatic, prostate, cervical, brain, liver, blood, ovary, bone, endometrial, oral, lung, eye, stomach, and kidney are the object of substantial ongoing review.

In addition to the anti-inflammatory response, sesquiterpene lactones — closely related to sesquiterpenic acids in chemical class — have been found to sensitize tumor cells to conventional drug treatments.

Evidence strength: In vitro and animal models only. No completed, published human clinical trials specifically targeting sesquiterpenic acids as anticancer agents exist at the time of writing. Research in this area is active but remains in early preclinical stages.

7.8 Metabolic Syndrome

Selected sesquiterpene lactones have been experimentally validated for biological activities related to risk factors of metabolic syndrome; the potential beneficial effects demonstrate that these substances represent remarkable compounds with a diversity of molecular structure and high biological activity, providing new insights into the possible role in metabolic syndrome.

In a systematic review and meta-analysis of various Ayurvedic herbs used to combat diabetes, Boswellia serrata was found to lower glycated hemoglobin levels compared to controls.

Evidence strength: Preliminary and largely indirect. Evidence is primarily from in vitro, animal, and small-scale human studies. The specific contribution of the sesquiterpenic acid fraction — as distinct from the whole plant preparation — has not been well-isolated in clinical trials.

7.9 Neuroprotection and Anticonvulsant Effects

In larval zebrafish, Valeriana officinalis and valerenic acid have been found to reverse PTZ-induced alterations in swimming behavior; moreover, the effects of PTZ on the immediate early genes c-fos, bdnf, and npas4 have been found to be reversed by valerenic acid.

The potential of valerian extract as a natural alternative or adjunct to conventional pharmacotherapies for CNS disorders is supported by its favorable safety profile, nonaddictive nature, and lack of withdrawal symptoms upon discontinuation.

Evidence strength: Preclinical. Anticonvulsant data are currently from animal (rodent and zebrafish) models only. No completed human trials for this indication exist.

8. Body Systems and Health Areas

• Central Nervous System: Sleep regulation, anxiolysis, anticonvulsant potential — primarily via GABAergic and adenosinergic mechanisms (valerenic acid).
• Musculoskeletal System: Joint pain and inflammation, osteoarthritis, rheumatoid arthritis — via 5-lipoxygenase and NF-κB inhibition (boswellic acids).
• Gastrointestinal System: Inflammatory bowel conditions (Crohn's disease, ulcerative colitis) — via anti-inflammatory leukotriene pathway modulation (boswellic acids).
• Respiratory System: Asthma, chronic bronchitis — via leukotriene synthesis inhibition (boswellic acids).
• Immune/Inflammatory System: Broad immunomodulatory effects; anti-inflammatory activities, as well as modulations of the immune systems, make sesquiterpene lactones and related compounds attractive in pharmaceutical use.
• Oncology (preclinical): Induction of apoptosis in tumor cell lines; sensitization to chemotherapy.
• Dermatological System: In dermatological conditions such as eczema and psoriasis, boswellic acid-based treatments were reported to alleviate erythema, scaling, and pruritus with good tolerability.

9. Dosage Forms and Doses Reported in Studies

The following dosages are reported from cited studies and should not be construed as general recommendations.

9.1 Valerenic Acid / Valerian Extract

• In a pharmacokinetic interaction study, two 500-mg valerian tablets (1000 mg total) were administered nightly for 14 days; each tablet contained 5.51 mg of valerenic acid (total 11.02 mg valerenic acid nightly).
• A tested clinical preparation consisted of a valerian capsule of 250 mg extract corresponding to 3.48 mg valerenic acid per capsule.
• Valerian is also considered useful as an anxiolytic when administered during the daytime at doses up to 250 mg three times per day.

9.2 Boswellic Acids / Boswellia serrata Extract

• Boswellia has been most often studied at dosages of 100–250 mg/day of the Aflapin and 5-Loxin formulations.
• Symptomatic improvements have been reported with doses up to 6 g of B. serrata in clinical comparison studies.
• In a 90-day randomized double-blind multicenter trial, participants were randomly assigned to receive Boswellia serrata 300 mg plus Apium graveolens L. extract as a nutraceutical formulation.

10. Safety Considerations and Interactions

10.1 General Tolerability of Valerian / Valerenic Acid

Valerian has been extremely safe in clinical trials, with a side effect rate similar to placebo; the most common adverse effects seem to be gastrointestinal distress, headache, dizziness, and morning hangover (at high doses).

10.2 Hepatotoxicity

Adverse reactions associated with valerian include headache, diarrhea, and other gastrointestinal complaints, daytime sedation/dullness, impaired alertness, depression, irritability, dizziness, sweating, and heart palpitations. Rare case reports of hepatotoxicity associated with valerian use have appeared in the literature (Cohen & Del Toro, 2008; Vassiliadis et al., 2009). Data showed the inductive effect of valerian on cytochrome P450 (CYP) 3A4 and 2D6 enzymes in vitro, which should be seen with caution since alterations of CYP activity could affect the disposition of conventional pharmaceuticals; CYP3A4 is involved in metabolism of over 60% of all therapeutically used drugs.

10.3 CYP450 Drug Interaction Evidence

A study assessed the influence of valerian extract on the activity of the drug-metabolizing enzymes CYP2D6 and CYP3A4, administering probe drugs dextromethorphan (30 mg; CYP2D6) and alprazolam (2 mg; CYP3A4) to 12 healthy volunteers at baseline and again after two 500-mg valerian tablets nightly for 14 days. The CYP2D6 metabolic ratio did not significantly change (p > 0.05); however, for alprazolam, the maximum concentration in plasma was significantly increased after valerian treatment (25 ± 7 ng/mL versus 31 ± 8 ng/mL; p < 0.05).

In vitro studies assessing valerenic acid have not supported any significant effects upon CYP3A4 or other P450 isoforms.

Valerenic acid significantly inhibited glucuronidation by both microsomes and UGTs with the rather high concentration of 1 mg/mL; due to this fact and the very high glucuronidation capacity of the liver, a clinical relevance of these results cannot be assumed.

In vitro reports indicate that valerian inhibits CYP2D6 and CYP3A4 and may affect the serum concentration of drugs metabolized by these enzymes; valerian also inhibits P-glycoprotein (P-gp) transporters, which may elevate the intracellular concentration of substrate drugs, and modulates UGT enzymes in vitro, potentially enhancing the side effects of drugs metabolized by them.

10.4 CNS Depressant Additive Effects

Given valerenic acid's role as a positive allosteric modulator of GABA_A receptors, additive or synergistic CNS depression with benzodiazepines, barbiturates, alcohol, and other sedative agents is a pharmacologically plausible concern. The study of valerian GABA studies in both laboratory and clinical contexts shows that modulation of GABA_A receptors has potential benefits but also clear risks when combined with other sedative agents.

10.5 Tolerability of Boswellic Acids

Subacute and subchronic toxicity studies showed that repeated administration of standardized Boswellia serrata extract was generally well tolerated in preclinical models. Clinically, gastrointestinal adverse events (nausea, abdominal pain, diarrhea) have been the most commonly reported side effects across trials, and are generally mild to moderate in severity.

10.6 Bioavailability Limitations

Questions remain about the efficacy of sesquiterpene lactones as anti-inflammatory drugs; the concentrations upon which they are pharmacologically active are not well-described, reinforcing the importance of studying the pharmacokinetic (ADME — absorption, distribution, metabolism, excretion) profiles of these molecules.

11. Research Limitations and Evidence Gaps

Across the sesquiterpenic acid class, several important limitations apply to the current evidence base:

• Most clinical evidence involves complex multi-constituent plant extracts rather than isolated sesquiterpenic acids, making it difficult to attribute observed effects specifically to the acid fraction.
• The findings seem promising; however, questions remain about the efficacy of sesquiterpene lactones as anti-inflammatory drugs, and the concentrations upon which they are pharmacologically active are not well-described.
• Standardization of extract preparations varies widely across commercial products and study preparations, hindering cross-trial comparisons.
• Long-term safety data (beyond several months) are not available for most sesquiterpenic acid-rich preparations in human populations.
• In vitro and animal efficacy data for antimicrobial and anticancer applications have not yet been translated into clinical trials.

References

• Ramos MFL et al. (2022). Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones. Molecules, 27(3), 1142. PMC8839508.
• ScienceDirect Topics: Sesquiterpenoid — an overview.
• ScienceDirect Topics: Sesquiterpene — an overview.
• de Pascual-Teresa J et al. (2001). Sesquiterpenic acids from Leucanthemopsis pulverulenta. Tetrahedron.
• Choudhary A et al. (2021). Chemistry and Pharmacological Activity of Sesquiterpenoids from the Chrysanthemum Genus. Molecules, 26(10), 3038. PMC8161347.
• Salomé-Abarca LF et al. (2025). Valerenic Acid and Pinoresinol as Positive Allosteric Modulators: Unlocking the Sleep-Promoting Potential of Valerian Extract Ze 911. PMC12155840.
• Etsassala NGER et al. (2021). Ameliorative Effects of Valerenic Acid on Oxidative Stress Induced in HepG2 Cells. PMC8151918.
• Hassani FV et al. (2021). Effects of Valerian on Sleep Quality, Depression, and State Anxiety in Hemodialysis Patients. PMC8077445.
• Khom S et al. (2007). Valerenic acid potentiates and inhibits GABAA receptors: Molecular mechanism and subunit specificity. Neuropharmacology.
• Hintersteiner J et al. (2016). Analysis of β-Subunit-dependent GABAA Receptor Modulation and Behavioral Effects of Valerenic Acid Derivatives. PMC4885513.
• Khom S et al. (2010). Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands. PMC2962817.
• Siddiqui MZ. (2011). Boswellia Serrata, A Potential Antiinflammatory Agent: An Overview. PMC3309643.
• Khalil F et al. (2025). From bench to bedside, boswellic acids in anti-inflammatory therapy. Frontiers in Pharmacology. PMC12669112.
• Wang T et al. (2020). Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. PMC7368679.
• Krishnaraju AV et al. (2024). A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days. Frontiers in Pharmacology. PMC11291344.
• Deshpande S et al. (2025). Efficacy and Safety of Boswellia serrata and Apium graveolens Extract Against Knee Osteoarthritis. PMC11880083.
• Donovan JL et al. (2004). Multiple night-time doses of valerian had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metabolism and Disposition, 32(12):1333–1336. PubMed 15328251.
• Kelber O et al. (2014). Valerian: No Evidence for Clinically Relevant Interactions. Evidence-Based Complementary and Alternative Medicine. PMC4100259.
• Donovan JL et al. (2004). Multiple Night-Time Doses of Valerian had Minimal Effects on CYP3A4 Activity. ScienceDirect.
• Yang Y et al. (2022). Antibacterial and Antifungal Sesquiterpenoids: Chemistry, Resource, and Activity. Biomolecules. PMC9496053.
• Bradacs G et al. (2023). Antibacterial and Antifungal Terpenes from Medicinal Angiosperms of Asia and the Pacific. PMC10180233.
• Ciocarlan A et al. (2022). Recent Advances Regarding Molecular Mechanisms of Triterpenic Acids: A Review (Part I). PMC9322890.
• Singh S et al. (2021). Sesquiterpenes and their derivatives — natural anticancer compounds: An update. Pharmacological Research.
• Nature's Brewery to Bedtime: The Role of Hops in GABAA Receptor Modulation and Sleep Promotion. arXiv preprint 2402.02129.
• HerbalGram: Valerian Extract Containing 2% Valerenic Acid May Improve Sleep Quality in Adults (2024).
• Wikipedia: Boswellic acid.
• Examine.com: Boswellia — benefits, dosage, and side effects.
• ScienceDirect Topics: Valerenic Acid — an overview.